Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types.
### Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
* Adjunctive treatment of other seizure types (e.g., myoclonic, atonic, absence seizures) where appropriate.
### Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Gradually increase dose every week based on clinical response and tolerability.
* **Maintenance Dose:** Typically 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg daily).
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **2 to less than 10 years:**
* Initial Dose: 5 mg once daily.
* Maintenance Dose: Titrate up to 10 mg twice daily.
* **10 years and older:**
* Initial Dose: 10 mg once daily.
* Maintenance Dose: Titrate up to 20 mg twice daily.
* **Other Seizure Types:** Dosing may vary. Consult specific guidelines or prescribing information. Doses should be individualized.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, particularly in severe impairment.
* **Renal Impairment:** Use with caution. Dose may need to be adjusted based on renal function.
* **Elderly:** Start with lower doses and titrate slowly due to potential increased sensitivity.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
### Adverse Effects
Common: Somnolence, agitation, aggression, irritability, difficulty concentrating, ataxia, decreased appetite, cough.
Serious: Stevens-Johnson syndrome, toxic epidermal necrolysis, severe skin reactions, suicidal behavior/ideation, withdrawal symptoms, paradoxical reactions.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of profound sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **CNS Stimulants:** May decrease the effectiveness of clobazam.
### Monitoring
* Monitor for seizure frequency and severity.
* Assess for signs of somnolence, behavioral changes, and cognitive impairment.
* Observe for signs of withdrawal upon discontinuation.
* Monitor for skin reactions, especially in the initial weeks of treatment.
### Clinical Pearls
* Clobazam has a longer half-life compared to other benzodiazepines, which may allow for once or twice daily dosing.
* Withdrawal symptoms can occur, even with gradual tapering. Tapering should be done slowly under medical supervision.
* Risk of serious skin reactions exists; patients and caregivers should be educated to discontinue immediately and seek medical attention if a rash develops.
* Use with caution in patients with a history of drug abuse.
***
*This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines.*
